NAGE insider transaction filings

Niagen Bioscience, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-08. Screen NAGE transaction legs live →

FiledFormInsiderReported transactionsSource
2026-07-084Lopez Carlos Luis — SVP, General CounselGrant/award (A): 2,314 @ $2.71EDGAR
2026-07-084Pamir Ozan — Chief Financial OfficerGrant/award (A): 4,255 @ $2.71EDGAR
2026-07-084Fried Robert N — Chief Executive Officer, DirectorGrant/award (A): 1,106 @ $2.71EDGAR
2026-06-264Shahbazi Hamed — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-06-264Cohen Ann — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-06-264Ng Wang Yu Gary — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-06-264Patrick Kristin — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-06-264YU Wing Tak Wendy — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-06-264Jaksch Frank L Jr — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-06-264Rubin Steven D — DirectorGrant/award (A): 31,746 (derivative) @ $0EDGAR
2026-04-274Fried Robert N — Chief Executive Officer, DirectorOption exercise (M): 20,000 @ $2.61 · Option exercise (M): 20,000 (derivative) @ $0EDGAR
2026-02-244Lopez Carlos Luis — SVP, General CounselGrant/award (A): 41,420 (derivative) @ $0EDGAR
2026-02-244Pamir Ozan — Chief Financial OfficerGrant/award (A): 62,131 (derivative) @ $0EDGAR
2026-02-244Fried Robert N — Chief Executive Officer, DirectorGrant/award (A): 503,937 (derivative) @ $0EDGAR
2025-11-174Pamir Ozan — Chief Financial OfficerPurchase (P): 4,464.96 @ $6.81 · Purchase (P): 2,220.44 @ $6.85EDGAR
2025-07-034Shahbazi Hamed — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-06-264YU Wing Tak Wendy — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-06-264Patrick Kristin — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-06-254Ng Wang Yu Gary — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-06-254Cohen Ann — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-06-254Jaksch Frank L Jr — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-06-254Rubin Steven D — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2025-04-094Fried Robert N — Chief Executive Officer, DirectorOption exercise (M): 66,667 @ $3.30 · Option exercise (M): 66,667 (derivative) @ $0EDGAR

Recent 8-K events — Niagen Bioscience, Inc.

FiledFormItems reportedSource
2026-08-048-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-298-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-068-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-198-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-048-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-268-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-228-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-068-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-048-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-10-068-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=NAGE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →